Skip to Main Content
Table 2

Response rates vs. age in Phase 2 studies of 142 patients with CD33 positive AML in first relapse treated with gemtuzumab ozogamicin

Type of remission201/202/203 (n = 142)<60 yr (n = 62)≥60 yr (n = 80)
CR    
 No. (%) of patients 23 (16) 11/62 (18) 12/80 (15) 
 95% CIsa (11, 23) (9, 30) (8, 25) 
CRp    
 No. (%) of patients 19 (13) 10/62 (16) 9/80 (11) 
 95% CIs (8, 20) (8, 28) (5, 20) 
OR (CR + CRp)    
 No. (%) of patients 42 (30) 21/62 (34) 21/80 (26) 
 95% CIs (22, 38) (22, 47) (17, 37) 
Type of remission201/202/203 (n = 142)<60 yr (n = 62)≥60 yr (n = 80)
CR    
 No. (%) of patients 23 (16) 11/62 (18) 12/80 (15) 
 95% CIsa (11, 23) (9, 30) (8, 25) 
CRp    
 No. (%) of patients 19 (13) 10/62 (16) 9/80 (11) 
 95% CIs (8, 20) (8, 28) (5, 20) 
OR (CR + CRp)    
 No. (%) of patients 42 (30) 21/62 (34) 21/80 (26) 
 95% CIs (22, 38) (22, 47) (17, 37) 
a

CI, confidence interval.

Close Modal

or Create an Account

Close Modal
Close Modal